Abstract
Preventing and managing CVD requires a multifaceted approach that addresses risk factors such as smoking, inactivity, poor diet, and hypertension. Personalized approaches such as pharmacogenomics have the potential to improve efficacy and safety of CVD medications, reduce the burden of adverse events and optimize patient outcomes. This chapter provides evidence-based recommendation for medication selection and dosing based on pharmacogenomic data. It also explores the current evidence base for lifestyle precision medicine and prevention of cardiac arrhythmia.
Original language | English (US) |
---|---|
Title of host publication | Comprehensive Precision Medicine, First Edition, Volume 1-2 |
Publisher | Elsevier |
Pages | V2-436-V2-442 |
Volume | 1-2 |
ISBN (Electronic) | 9780128240106 |
DOIs | |
State | Published - Jan 1 2023 |
Keywords
- Anticoagulation
- Beta blockers
- Clinical decision support
- Clopidogrel
- Drug induced arrhythmias
- Familial cardiac arrhythmias
- Lifestyle precision medicine
- Long QT
- Pharmacogenomics
- Statin therapy
ASJC Scopus subject areas
- General Agricultural and Biological Sciences
- General Biochemistry, Genetics and Molecular Biology